Clinical Trial Detail

NCT ID NCT01177397
Title Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene Corporation
Indications

estrogen-receptor positive breast cancer

neuroendocrine tumor

progesterone-receptor positive breast cancer

hepatocellular carcinoma

glioblastoma multiforme

diffuse large B-cell lymphoma

Advanced Solid Tumor

multiple myeloma

Her2-receptor positive breast cancer

lung non-small cell carcinoma

Therapies

Onatasertib

Age Groups: adult senior

No variant requirements are available.